Who are Carmustine BCNU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CCNU, Lomustine Chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carmustine-bcnu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Carmustine BCNU — Competitive Intelligence Brief

Carmustine BCNU (Carmustine BCNU) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrosourea alkylating agent. Area: Oncology.

phase 3 Nitrosourea alkylating agent DNA (non-specific alkylating agent) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Carmustine BCNU (Carmustine BCNU) — Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie. Carmustine is a nitrosourea alkylating agent that cross-links DNA strands, preventing cell replication and inducing cancer cell death.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Carmustine BCNU TARGET	Carmustine BCNU	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie	phase 3	Nitrosourea alkylating agent	DNA (non-specific alkylating agent)
CCNU	CCNU	Radiation Therapy Oncology Group	phase 3	Nitrosourea alkylating agent	DNA (non-selective alkylating agent)
Lomustine Chemotherapy	Lomustine Chemotherapy	AstraZeneca	phase 3	Nitrosourea alkylating agent	DNA (non-selective alkylating agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitrosourea alkylating agent class)

AstraZeneca · 1 drug in this class
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie · 1 drug in this class
Radiation Therapy Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carmustine BCNU — Competitive Intelligence Brief. https://druglandscape.com/ci/carmustine-bcnu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab